Cyclodextrins as therapeutic drugs for treating lipid metabolism disorders
This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially
Tag: clinical trials
Merger of Cyclo Therapeutics and Applied Molecular Transport
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
Cyclodextrins and derivatives in drug delivery: New developments, relevant clinical trials, and advanced products
Novel cyclodextrin derivatives, such as polyrotaxanes, cyclodextrin-polymer conjugates, and thiolated cyclodextrins, are among the most promising candidates in drug delivery.
Serving patient’s safety and comfort: Effects of sugammadex vs. neostigmine on postoperative nausea, vomiting and pulmonary complications following general anesthesia.
A recent study published by Korean scientists compared the effect of sugammadex with that of neostigmine in terms of the
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator
Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
The aim of this report is to review the literature and shed light on the uncertainties surrounding the use of
Cyclo Therapeutics on Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase
Reviews on remdesivir in Covid-19 treatment
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
Gilead debates WHO results on low effectivity of remdesivir in Covid-19 mortality rate
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis
The systematic review published recently in Clinical Microbiology and Infection was based on 29 articles [1]. All studies except one